C2 (21% of DLBCL) is a mixture of GCB and ABC DLBCL, which share lesions in genes involved in the DNA damage response (TP53 inactivation), cell cycle (inactivation of CDKN2A and RB1), PI3K/AKT signaling (MIR17HG amplifications), and apoptosis (MCL1 gain or amplifications). The gene discussed is CDKN2A; the disease is diffuse large B-cell lymphoma.